Plain-English translation of NCT05867004 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This trial is testing whether adding infliximab (a TNF-blocking medication) to immune checkpoint inhibitor therapy can help more people with advanced melanoma fight their cancer. About 60% of melanoma patients don't respond well to immune checkpoint inhibitors alone, so researchers want to see if this combination treatment could work better. The study will also look at whether this medication combination causes fewer serious side effects.
Most people with advanced melanoma don't respond to current immune therapies, and those who do often experience severe side effects. Lab studies suggest that blocking TNF alongside immune checkpoint inhibitors might wake up the immune system more effectively and cause fewer complications.
You likely qualify if…
You likely don't qualify if…
You would be participating as part of two linked clinical trials. Your specific visits, tests, and treatment schedule would be determined by the TICIMEL or MELANFα trial you're enrolled in. You would receive the combination of medications as prescribed and attend regular appointments for monitoring, blood tests, and scans to see how you're responding.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment target
~100 participants
Started
January 2023
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bruno SEGUI, Pr
Cancer Research Center of Toulouse
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.